Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 14, 2011

Premium

TessArae has appointed Thomas Richards as president.
Richards has held faculty positions at Stanford University Medical Center and the University of California San Francisco Medical Center, where he currently practices as an assistant clinical professor in the department of emergency medicine.

Prior to earning an MD at Harvard Medical School, Richards was an investment banker in the mergers and acquisitions departments of several firms, including Lazard Freres, UBS Securities, and SG Cowen Securities.

From 2006 until 2010, he served on the board of directors of Cowen Group, where he was a member of the audit and corporate governance committees.


Ronald Davis has won the Gruber Genetics Prize, which is awarded for pioneering work that advances the fields of molecular genetics and genomics.

Davis, who has been director of the Stanford Genome Technology Center since 1994, will receive the $500,000 award for his efforts in developing DNA mapping methods, for his studies of ways to sequence genomic variants in humans and other animals, for his contribution in developing the first microarray technologies, and the work his lab has done in sequencing yeast chromosomes, the Escherichia coli genome, and other genomes.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.